Thus, the role of IL-22 in the context of chronic inflammation during IBD needs to be carefully re-evaluated, and the supplementation of exogenous IL-22, especially in an Fc fusion with long serum half-life, to patients with active colitis should be re-considered with extreme caution. The gene discussed is IL22; the disease is inflammatory bowel disease.